This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nguyen, M. H.
Right arrow Articles by Yu, C. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nguyen, M. H.
Right arrow Articles by Yu, C. Y.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 1998, p. 471-472, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

In Vitro Comparative Efficacy of Voriconazole and Itraconazole against Fluconazole-Susceptible and -Resistant Cryptococcus neoformans Isolates

M. Hong Nguyen* and Christine Y. Yu

Department of Medicine, Division of Infectious Disease, University of Florida College of Medicine, and VA Medical Center, Gainesville, Florida

Received 15 September 1997/Returned for modification 25 September 1997/Accepted 1 December 1997

In vitro susceptibility testing for 50 clinical isolates of fluconazole-susceptible or -resistant Cryptococcus neoformans was performed with itraconazole and voriconazole. Voriconazole was more potent than itraconazole for fluconazole-susceptible isolates and as potent as itraconazole for fluconazole-susceptible dose-dependent isolates and for fluconazole-resistant isolates. For fluconazole-resistant isolates, the voriconazole and itraconazole MICs ranged from 1 to 2 µg/ml.

* Corresponding author. Mailing address: Department of Medicine, University of Florida College of Medicine, P.O. Box 100277, JHMHC, Gainesville, FL 32610. Phone: (352) 379-4027. Fax: (352) 379-4015. E-mail: nguyemt{at}medicine.ufl.edu.

Antimicrobial Agents and Chemotherapy, February 1998, p. 471-472, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Illnait-Zaragozi, M.-T., Martinez, G. F., Curfs-Breuker, I., Fernandez, C. M., Boekhout, T., Meis, J. F. (2008). In Vitro Activity of the New Azole Isavuconazole (BAL4815) Compared with Six Other Antifungal Agents against 162 Cryptococcus neoformans Isolates from Cuba. Antimicrob. Agents Chemother. 52: 1580-1582 [Abstract] [Full Text]  
  • Dias, A. L. T., Matsumoto, F. E., Melhem, M. S. C., da Silva, E. G., Auler, M. E., de Siqueira, A. M., Paula, C. R. (2006). Comparative analysis of Etest and broth microdilution method (AFST-EUCAST) for trends in antifungal drug susceptibility testing of Brazilian Cryptococcus neoformans isolates.. J Med Microbiol 55: 1693-1699 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., Doern, G. V., Diekema, D. J. (2005). Global Trends in the Antifungal Susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol. 43: 2163-2167 [Abstract] [Full Text]  
  • van Duin, D., Cleare, W., Zaragoza, O., Casadevall, A., Nosanchuk, J. D. (2004). Effects of Voriconazole on Cryptococcus neoformans. Antimicrob. Agents Chemother. 48: 2014-2020 [Abstract] [Full Text]  
  • Pearson, M. M, Rogers, P D., Cleary, J. D, Chapman, S. W (2003). Voriconazole: A New Triazole Antifungal Agent. The Annals of Pharmacotherapy 37: 420-432 [Abstract] [Full Text]  
  • Purkins, L., Wood, N., Ghahramani, P., Greenhalgh, K., Allen, M. J., Kleinermans, D. (2002). Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens. Antimicrob. Agents Chemother. 46: 2546-2553 [Abstract] [Full Text]  
  • Manavathu, E. K., Dimmock, J. R., Vashishtha, S. C., Chandrasekar, P. H. (2001). Inhibition of H+-ATPase-mediated proton pumping in Cryptococcus neoformans by a novel conjugated styryl ketone. J Antimicrob Chemother 47: 491-494 [Abstract] [Full Text]  
  • Yamazumi, T., Pfaller, M. A., Messer, S. A., Houston, A., Hollis, R. J., Jones, R. N. (2000). In Vitro Activities of Ravuconazole (BMS-207147) against 541 Clinical Isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 44: 2883-2886 [Abstract] [Full Text]  
  • Manavathu, E. K., Cutright, J. L., Loebenberg, D., Chandrasekar, P. H. (2000). A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 46: 229-234 [Abstract] [Full Text]  
  • REIS, A., SUNDMACHER, R., TINTELNOT, K., AGOSTINI, H., JENSEN, H. E., ALTHAUS, C. (2000). Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol 84: 928d-928 [Full Text]  
  • Li, R.-K., Ciblak, M. A., Nordoff, N., Pasarell, L., Warnock, D. W., McGinnis, M. R. (2000). In Vitro Activities of Voriconazole, Itraconazole, and Amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob. Agents Chemother. 44: 1734-1736 [Abstract] [Full Text]  
  • Perea, S., Pennick, G. J., Modak, A., Fothergill, A. W., Sutton, D. A., Sheehan, D. J., Rinaldi, M. G. (2000). Comparison of High-Performance Liquid Chromatographic and Microbiological Methods for Determination of Voriconazole Levels in Plasma. Antimicrob. Agents Chemother. 44: 1209-1213 [Abstract] [Full Text]  
  • Chiou, C. C., Groll, A. H., Walsh, T. J. (2000). New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer. The Oncologist 5: 120-135 [Abstract] [Full Text]  
  • Lozano-Chiu, M., Arikan, S., Paetznick, V. L., Anaissie, E. J., Rex, J. H. (1999). Optimizing Voriconazole Susceptibility Testing of Candida: Effects of Incubation Time, Endpoint Rule, Species of Candida, and Level of Fluconazole Susceptibility. J. Clin. Microbiol. 37: 2755-2759 [Abstract] [Full Text]  
  • Mondon, P., Petter, R., Amalfitano, G., Luzzati, R., Concia, E., Polacheck, I., Kwon-Chung, K. J. (1999). Heteroresistance to Fluconazole and Voriconazole in Cryptococcus neoformans. Antimicrob. Agents Chemother. 43: 1856-1861 [Abstract] [Full Text]  
  • Sheehan, D. J., Hitchcock, C. A., Sibley, C. M. (1999). Current and Emerging Azole Antifungal Agents. Clin. Microbiol. Rev. 12: 40-79 [Abstract] [Full Text]  
  • Pfaller, M. A., Zhang, J., Messer, S. A., Brandt, M. E., Hajjeh, R. A., Jessup, C. J., Tumberland, M., Mbidde, E. K., Ghannoum, M. A. (1999). In Vitro Activities of Voriconazole, Fluconazole, and Itraconazole against 566 Clinical Isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob. Agents Chemother. 43: 169-171 [Abstract] [Full Text]  
  • Jessup, C. J., Pfaller, M. A., Messer, S. A., Zhang, J., Tumberland, M., Mbidde, E. K., Ghannoum, M. A. (1998). Fluconazole Susceptibility Testing of Cryptococcus neoformans: Comparison of Two Broth Microdilution Methods and Clinical Correlates among Isolates from Ugandan AIDS Patients. J. Clin. Microbiol. 36: 2874-2876 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»